-
Reviews
Back to Reviews
-
What are the main claims of the paper and how important are they?
The author reviewd the action of bromocriptin, the drug of anti-hyperprolactinaemia, based on in vivo and in vitro studies including clinical. Althogugh there are many side effects by high dose of bromocriptin such as psychiatric disturbances (anxiety, depression, confusion, auditory hallucination, insomnia, somnolence etc.), erythromelagia and dyskinesia, the auhter favoured the use of bromocriptin to the patient of hyperprolactinaemia due to its mild and lnog duration effects.
-
Are these claims novel? If not, please specify papers that weaken the claims to the originality of this one.
NA (review article)
-
Are the claims properly placed in the context of the previous literature?
Yes
-
Do the results support the claims? If not, what other evidence is required?
Yes
-
If a protocol is provided, for example for a randomized controlled trial, are there any important deviations from it? If so, have the authors explained adequately why the deviations occurred?
NA
-
Is the methodology valid? Does the paper offer enough details of its methodology that its experiments or its analyses could be reproduced?
NA(review article)
-
Would any other experiments or additional information improve the paper? How much better would the paper be if this extra work was done, and how difficult would such work be to do, or to provide?
NA(review article)
-
Is this paper outstanding in its discipline? (For example, would you like to see this work presented in a seminar at your hospital or university? Do you feel these results need to be incorporated in your next general lecture on the subject?) If yes, what makes it outstanding? If not, why not?
NA
-
Other Comments:
This review is dealing with wide range of the theme. Despite the disadvantage of life long usage, bromocriptine has been thought to be valuable treatment especially for the patient of hyperprolactinaemia. New drugs (dopamin agonists) are compared both in their duration of action, but also in thier effectiveness in prolactin reduction and also tumor (prolactinomas) size reduction. In all the dopamine agonists, carbergoline has the most effectiveness in decreasing (normalizing) prolactin levels of patients who are resistant to bromcriptine, due to higher binding affinity to dopamine receptor than the latter. However, in this moment it is reasnoble for the author to think that practically bromocriptine is still beneficial to the first line treatment for hyperlproactinaemia. Because by far the actions of bromocriptine has been extensively studied in vivo and in vitro, and in clinical treatment.
-
Competing interests:
None
-
Invited by the author to review this article? :
No -
Have you previously published on this or a similar topic?:
No
-
References:
No
-
Experience and credentials in the specific area of science:
Capsaicin and Pain
- How to cite: Hiura A .Bromocriptin: Past and Present: From the In Vitro and In Vivo Experimental Studies to the Clinical Data[Review of the article 'Bromocriptine: Past and present : From the In Vitro and In Vivo Experimental Studies to the Clinical Data ' by Venetikou M].WebmedCentral 2013;4(2):WMCRW002511
All site content, except where otherwise noted, is licensed under a
The article deals with the history of bromocriptine and its present use
Yes
Yes
Yes
NA
NA
Sections dealing with Parkinson's Disease are too short and understimates the importance that this drug have had for this disease. It should also be acknowledged that it is now a second line drug for this disease. Adverse event section may also be lenghtened by further commenting on AEs observed in these patients, such as daytime somnolence or impulse control disorders.
I believe that is a complete review about the subject, mostly orientated to the endocrinological uses of the drug. It may be worth stating this in the title.
NA
None
No
Yes
Adverse drug reactions to dopamine agonists: a comparative study in the French Pharmacovigilance Database. Perez-Lloret S, Bondon-Guitton E, Rascol O, Montastruc JL; French Association of Regional Pharmacovigilance Centers. Mov Disord. 2010 Sep 15;25(12):1876-80. doi: 10.1002/mds.23204.
None